TrialDiabetes, obesity & metabolism2019

Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.

Eiichi Araki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.